Conjugation of glucosylated polymer chains to checkpoint blockade antibodies augments their efficacy and specificity for glioblastoma

Combination immunotherapy strategies for glioblastoma

(2021) Hok Yee Chan et al.   JOURNAL OF NEURO-ONCOLOGY

Immune Checkpoint Inhibitor‐Based Strategies for Synergistic Cancer Therapy

(2021) Mengying He et al.   Advanced Healthcare Materials

Temporal and spatial modulation of the tumor and systemic immune response in the murine Gl261 glioma model

(2020) Kelly J. McKelvey et al.   PLoS One

Immune-related adverse events of checkpoint inhibitors

(2020) Manuel Ramos-Casals et al.   Nature Reviews Disease Primers

Translational Nanomedicine Boosts Anti-PD1 Therapy to Eradicate Orthotopic PTEN-Negative Glioblastoma

(2020) Hiroaki Kinoh et al.   ACS Nano

PD-L1 Expression in Glioblastoma, the Clinical and Prognostic Significance: A Systematic Literature Review and Meta-Analysis

(2020) Chengcheng Hao et al.   Frontiers in Oncology

The Prognostic and Therapeutic Value of PD-L1 in Glioma

(2019) Ruo Qiao Chen et al.   Frontiers in Pharmacology

PTEN Mutations Trigger Resistance to Immunotherapy

(2019) Feixiong Cheng et al.   TRENDS IN MOLECULAR MEDICINE

Challenges to curing primary brain tumours

(2019) Kenneth Aldape et al.   Nature Reviews Clinical Oncology

Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma

(2019) Junfei Zhao et al.   NATURE MEDICINE

Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy

(2019) Melvyn T. Chow et al.   IMMUNITY

Glucose transporter 1-mediated vascular translocation of nanomedicines enhances accumulation and efficacy in solid tumors

(2019) Kazumi Suzuki et al.   JOURNAL OF CONTROLLED RELEASE

A coiled-coil masking domain for selective activation of therapeutic antibodies

(2019) Vivian H. Trang et al.   NATURE BIOTECHNOLOGY

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

(2019) Filipe Martins et al.   Nature Reviews Clinical Oncology

Ligand‐Installed Nanocarriers toward Precision Therapy

(2019) Peng Mi et al.   ADVANCED MATERIALS

Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors

(2019) Denarda Dangaj et al.   CANCER CELL

Engineering nanoparticles to locally activate T cells in the tumor microenvironment

(2019) Dangge Wang et al.   Science Immunology

Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma

(2019) Peng Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease

(2018) Noha Abdel-Wahab et al.   ANNALS OF INTERNAL MEDICINE

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

(2018) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Current state of immunotherapy for glioblastoma

(2018) Michael Lim et al.   Nature Reviews Clinical Oncology

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

(2018) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial

(2017) James L Gulley et al.   LANCET ONCOLOGY

Antibody–drug conjugates in glioblastoma therapy: the right drugs to the right cells

(2017) Hui K. Gan et al.   Nature Reviews Clinical Oncology

Glycaemic control boosts glucosylated nanocarrier crossing the BBB into the brain

(2017) Y. Anraku et al.   Nature Communications

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

(2016) Howard L Kaufman et al.   LANCET ONCOLOGY

Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy

(2016) Yun Yang et al.   mAbs

Creation of an NCI comparative brain tumor consortium: informing the translation of new knowledge from canine to human brain tumor patients

(2016) Amy K. LeBlanc et al.   NEURO-ONCOLOGY

Dually pH/Reduction-Responsive Vesicles for Ultrahigh-Contrast Fluorescence Imaging and Thermo-Chemotherapy-Synergized Tumor Ablation

(2015) Aijun Zhu et al.   ACS Nano

28PDIdentifying the correct patient (pt) population for ABT-414: Biomarker assays for epidermal growth factor receptor (EGFR) in pts with glioblastoma (GBM)

(2015) L. Roberts-Rapp et al.   ANNALS OF ONCOLOGY

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

(2015) J. Naidoo et al.   ANNALS OF ONCOLOGY

Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression

(2015) Chih-Hao Chang et al.   CELL

Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency

(2015) Yun Yang et al.   mAbs

Metabolic reprogramming in glioblastoma: the influence of cancer metabolism on epigenetics and unanswered questions

(2015) Sameer Agnihotri et al.   NEURO-ONCOLOGY

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors

(2014) D. A. Wainwright et al.   CLINICAL CANCER RESEARCH

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma

(2014) Anna Sophie Berghoff et al.   NEURO-ONCOLOGY

Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma

(2014) A. P. Patel et al.   SCIENCE

EGFR Variant Heterogeneity in Glioblastoma Resolved through Single-Nucleus Sequencing

(2014) J. M. Francis et al.   Cancer Discovery

PD-L1 Expression by Neurons Nearby Tumors Indicates Better Prognosis in Glioblastoma Patients

(2013) Y. Liu et al.   JOURNAL OF NEUROSCIENCE

Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index

(2013) L. R. Desnoyers et al.   Science Translational Medicine

Glutathione levels in human tumors

(2012) Michael P. Gamcsik et al.   BIOMARKERS

Targeting of a Conformationally Exposed, Tumor-Specific Epitope of EGFR as a Strategy for Cancer Therapy

(2012) H. K. Gan et al.   CANCER RESEARCH

Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases

(2012) Oran Erster et al.   JOURNAL OF CONTROLLED RELEASE

The role of glutathione in brain tumor drug resistance

(2011) Donald S. Backos et al.   BIOCHEMICAL PHARMACOLOGY

FDA-approved poly(ethylene glycol)–protein conjugate drugs

(2011) Steevens N. S. Alconcel et al.   Polymer Chemistry

Prediction of protein secondary structure from circular dichroism using theoretically derived spectra

(2011) Caroline Louis-Jeune et al.   PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS

Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells

(2010) Lucia Ricci-Vitiani et al.   NATURE